Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02713789Phase 2Completed

Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED

Role: collaborator

NCT00495053Phase 1Terminated

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Role: collaborator

NCT01870037Phase 1Completed

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

Role: collaborator

All 3 trials loaded